Stay updated with the latest healthcare breakthroughs, including the FDA approval of insulin efsitora alfa-gobe (Onswik).
News|Articles|June 30, 2025
FDA News Recap: 5 Approvals to Know from the First Half of 2025
Author(s)Patrick Campbell
Fact checked by: Victoria Johnson
Discover groundbreaking FDA approvals in 2025 that redefine treatment standards, enhance patient care, and address critical public health needs.
Advertisement
Advertisement
The first half of 2025 has unfolded during a period of uncertainty in public health. From ongoing pressure on healthcare systems to workforce shortages and shifting regulatory dynamics, challenges remain on nearly every front. Yet even amid these headwinds, the pace of medical innovation continues—and in some cases, accelerates. The
Related to this article
Approval is based on 36-week data from BRAVE-AA-PEDS, in which 42% of patients on the 4 mg dose achieved a SALT score of 20 or less, compared with 5% on placebo.
Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.
The FDA has granted Priority Review to dersimelagon for EPP and XLP, setting a PDUFA date for late February 2027 as LEO Pharma completes its acquisition from Tanabe Pharma.
The approval, backed by FINE-ONE data showing a 28% UACR reduction at 6 months, is the first new CKD treatment for this group in 3 decades.
Stress led all triggers, and a sense of an impending attack was the most reliable prodrome in patients with HAE-C1INH in the US HAEA Scientific Registry.
The FDA approved once-daily oral zilurgisertib for FOP in patients aged 12 years and older after the phase 2 PROGRESS trial showed reduced new heterotopic ossification vs placebo.
Approval covers patients aged ≥2 years with frequently relapsing or steroid dependent disease in complete remission.
Advertisement
Advertisement